REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

BLA FilingRGX-202surabgene lomparvovecsura-vecPositive

AI Analysis

Summary

REGENXBIO reported Q2 2026 results with RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026, targeting potential accelerated approval in 2H 2027. Long-term data for surabgene lomparvovec (ABBV-RGX-314) demonstrated durable safety and efficacy.

Outcome Details

RGX-202 BLA submission on track for Q3 2026 initiation with potential accelerated approval in 2H 2027

Importance:7/10

Sentiment:

0.60

BLA_submissionDMDaccelerated_approvalgene_therapyQ2_2026_earningslong-term_data

Related Companies

$RGNX $ABBV

Read the original article

Published by PR Newswire Biotech on August 6, 2026 11:05 AM

Read Original